Pharma Two B Completes $8M Second Financing Round

Pharma Two B Ltd., a Rehovoth, Israel-based company that focuses on developing Fixed-Dose-Combinations (FDCs) of two or more drugs with complementary and synergistic effects, has completed its $8m second round of financing.

Backers include JK&B Capital, Michael Mittelman and Crossroad FCP-FIS.

Led by Founder & Chairman Mr. Ehud Marom, Pharma Two B focuses on Fixed-Dose-combinations of two or more drugs with complementary and synergistic effects, in two therapeutic areas with great unmet needs, Parkinson’s disease and Cancer.
The company intends to use the capital to continue the development of its Fixed-Dose-Combination product for the treatment of Parkinson’s disease, and complete the pivotal Phase IIb clinical trial as part of the US FDA 505(b)(2) regulatory pathway it chose to take.

FinSMEs

22/10/2012

Join the discussion